Co-founder and Chief Executive Officer, Ramakrishna Venugopalan, has a pioneering and successful track record of developing combination products and most recently headed the Combination Product and Drug Delivery teams at AbbVie. Krishna’s team, among other accomplishments, has developed over ten categories of combination products. Examples include prefilled syringes, autoinjectors, and on-body wearable injector presentations for Skyrizi® giving patients a choice for how they want to utilize the therapy, sustained release Ozurdex® implant delivered using an intravitreal injector/applicator, multidose preservative free dropper systems for various eye care products such as Vuity® or Restatsis®, and even drug delivery system for chronic infusion of foslevadopa/foscarbidopa solution or Vyalevä for Parkinson’s disease. He also led AbbVie through an end-to-end recrafting of the development and commercialization process for combination products including deploying a platform strategy that substantially de-risked development, accelerated timelines and proactively enabled scale-up. Krishna completed his PhD in Biomedical Engineering from University of Alabama at Birmingham (UAB), and his MBA from MIT’s Sloan School. He started his career as an academic at UAB where he developed a laboratory to support applied research and development of various types of minimally invasive interventional devices, such as stents for cardiac and neurological applications. Subsequently, he transitioned to industry, spending over 20 years in roles with increasing levels of responsibility at both J&J and AbbVie.